← All trials
NCT06770894
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 24, 2019
- Primary completion
- Oct 10, 2023
- Completion date
- Jan 24, 2024
- First posted
- Jan 13, 2025
- Last posted
- Jan 13, 2025
- Enrollment
- 132
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Roma La SapienzaLead sponsor
- University of Roma La SapienzaSponsor investigator
- Agenzia Italiana del FarmacoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.